Why This Seattle Biotech Could be an M&A Target Post author:Sam Post published:January 18, 2018 Post category:BioPharma Immune Design is a clinical-stage immunotherapy company. Source: BioSpace You Might Also Like How This Little Biopharma Could Beat Amgen, Teva to the Migraine Finish Line January 16, 2018 The Hype Behind Massachusetts Biotech Corbus' Sole Pipeline Drug March 16, 2017 Novartis AG Puts Cancer Hopes on 4 Star Scientists Poached From Harvard Last Year February 28, 2017
